ORIGINAL PAPER
Left atrial appendage thrombus in patients referred to electrical cardioversion for typical atrial flutter
1
Institute of Medical Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland Head of the Institute: Beata Kręcisz MD, PhD, Prof. JKU
Submission date: 2021-12-06
Final revision date: 2022-06-14
Acceptance date: 2022-06-17
Publication date: 2022-06-30
Medical Studies 2022;38(2):132-139
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Patients with atrial flutter (AFL) are at risk of stroke; however, the stratification of stroke risk is difficult. It remains unknown whether left atrial appendage thrombus (LAAT) in AFL patients on chronic oral anticoagulation (OAC) contributes significantly to that risk.
Aim of the research:
To assess the prevalence and predictors of LAAT, and its role in the prediction of mortality, stroke, and systemic thromboembolic events among consecutive AFL patients on OAC admitted for electrical cardioversion.
Material and methods:
This was a prospective, single-centre cohort study. The participants underwent transoesophageal echocardiography before electrical cardioversion. A total of 69 patients were enrolled. The primary outcome was the presence of LAAT. All participants were followed up for 12 months to evaluate the incidence of systemic thromboembolic events, stroke, and death.
Results:
Despite uninterrupted OAC, irrespective of the anticoagulant agent type, LAAT was present in 10.1% of patients referred for cardioversion due to typical AFL of > 48-hour duration. The significant predictor of LAAT was prior stroke/transient ischaemic attack/thromboembolic event (OR = 14.75; 95% CI: 2.17–108.33). No deaths, strokes, or systemic thromboembolic events occurred during the follow-up period.
Conclusions:
The predictive role of LAAT in relation to mortality, stroke, and systemic thromboembolic events among patients with AFL and chronic oral anticoagulation remains unclear.
Patients with atrial flutter (AFL) are at risk of stroke; however, the stratification of stroke risk is difficult. It remains unknown whether left atrial appendage thrombus (LAAT) in AFL patients on chronic oral anticoagulation (OAC) contributes significantly to that risk.
Aim of the research:
To assess the prevalence and predictors of LAAT, and its role in the prediction of mortality, stroke, and systemic thromboembolic events among consecutive AFL patients on OAC admitted for electrical cardioversion.
Material and methods:
This was a prospective, single-centre cohort study. The participants underwent transoesophageal echocardiography before electrical cardioversion. A total of 69 patients were enrolled. The primary outcome was the presence of LAAT. All participants were followed up for 12 months to evaluate the incidence of systemic thromboembolic events, stroke, and death.
Results:
Despite uninterrupted OAC, irrespective of the anticoagulant agent type, LAAT was present in 10.1% of patients referred for cardioversion due to typical AFL of > 48-hour duration. The significant predictor of LAAT was prior stroke/transient ischaemic attack/thromboembolic event (OR = 14.75; 95% CI: 2.17–108.33). No deaths, strokes, or systemic thromboembolic events occurred during the follow-up period.
Conclusions:
The predictive role of LAAT in relation to mortality, stroke, and systemic thromboembolic events among patients with AFL and chronic oral anticoagulation remains unclear.
REFERENCES (35)
1.
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, Calkins H, Corrado D, Deftereos SG, Diller GP, Gomez-Doblas JJ, Gorenek B, Grace A, Ho SY, Kaski JC, Kuck KH, Lambiase PD, Sacher F, Sarquella-Brugada G, Suwalski P, Zaza A, Group ESCSD. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 655-720.
2.
Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, Keegan R, Kim YH, Knight BP, Kuck KH, Lane DA, Lip GY, Malmborg H, Oral H, Pappone C, Themistoclakis S, Wood KA, Blomstrom-Lundqvist C, Gorenek B, Dagres N, Dan GA, Vos MA, Kudaiberdieva G, Crijns H, Roberts-Thomson K, Lin YJ, Vanegas D, Caorsi WR, Cronin E, Rickard J. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017; 19: 465-511.
3.
Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E, Vidaillet H. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36: 2242-2246.
4.
Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87: 346-349, A9.
5.
Gula LJ, Redfearn DP, Jenkyn KB, Allen B, Skanes AC, Leong-Sit P, Shariff SZ. Elevated incidence of atrial fibrillation and stroke in patients with atrial flutter – a population-based study. Can J Cardiol 2018; 34: 774-783.
6.
Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Mun- ger TM, Shen WK, Hammill SC, Friedman PA. The natural history of lone atrial flutter. Ann Intern Med 2004; 140: 265-268.
7.
Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, McManus DD, Sullivan LM, Seshadri S, Vasan RS, Benjamin EJ, Magnani JW. Atrial flutter: clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm 2016; 13: 233-240.
8.
Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmus- sen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015; 101: 1446-1455.
9.
Cresti A, Garcia-Fernandez MA, De Sensi F, Miracapil- lo G, Picchi A, Scalese M, Severi S. Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study. Europace 2016; 18: 450-456.
10.
Huang JJ, Reddy S, Truong TH, Suryanarayana P, Al- pert JS. Atrial appendage thrombosis risk is lower for atrial flutter compared with atrial fibrillation. Am J Med 2018; 131: 442e13-442e17.
11.
Kobayashi N, Kasahara M, Kasahara H, Ushimaru H, Ochi T, Saito M, Yaginuma T. Impaired atrial contraction in patients with atrial flutter and gradual recovery after cardioversion. Jpn Circ J 1998; 62: 15-20.
12.
Sychev OS, Borodai AA, Borodai ES. Detection of signs of thrombus formation in patients with typical atrial flutter. Kardiologiia 2015; 55: 56-60.
13.
Janion-Sadowska A, Turek Ł, Dudek A, Andrychowski J, Sadowski M. Atrial fibrillation and flutter – the state of the art. Part 2. Medical Studies 2021; 37: 239-249.
14.
Ghali WA, Wasil BI, Brant R, Exner DV, Cornuz J. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med 2005; 118: 101-107.
15.
Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography. Circulation 1997; 95: 962-966.
16.
Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997; 30: 1506-1511.
17.
Sakurai K, Hirai T, Nakagawa K, Kameyama T, Noza- wa T, Asanoi H, Inoue H. Prolonged activation of hemostatic markers following conversion of atrial flutter to sinus rhythm. Circ J 2004; 68: 1041-1044.
18.
European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angeli- ni A, Atar D, Colonna P, De Caterina R, De Sutter J, Goet- te A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
19.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Guidelines ESCCfP. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
20.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
21.
Heidbuchel H, Verhamme P, Alings M, Antz M, Die- ner HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirch- hof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.
22.
Kasprzak JD, Hoffman P, Płońska E, Szyszka A, Braksa- tor W, Gackowski A, Plewka M, Drożdż J, Gąsior Z, Pruszczyk P. In Poland Echokardiografia w praktyce klinicznej – Standardy Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego 2007. Kardiol Pol 2007; 65: 1142-1162.
23.
Anselmino M, Garberoglio L, Gili S, Bertaglia E, Stabile G, Marazzi R, Themistoclakis S, Solimene F, Frea S, Grosso Marra W, Morello M, Scaglione M, De Ponti R, Gaita F. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: a multicenter study. Int J Cardiol 2017; 241: 218-222.
24.
Seidl K, Rameken M, Drogemuller A, Vater M, Brandt A, Schwacke H, Bergmeier C, Zahn R, Senges J. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol 2002; 39: 1436-1442.
25.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Fo- ster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W, American Society of Echocardiography’s N, Standards C, Task Force on Chamber Q, American College of Cardiology Echocardiography C, American Heart A, European Association of Echocardiography ESoC. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
26.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation – Executive Summary. Circulation 2006; 114: 700-752.
27.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippa- tos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnlo- ser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikow- ski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50: e1-e88.
28.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, Members AATF. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-e267.
29.
Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23: 208-216.
30.
Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855.
31.
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
32.
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halpe- rin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nes- sel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G, Committee RAS, Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998-2006.
33.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH, Investigators XV. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35: 3346-3355.
34.
Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB, Committees A, Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082-1087.
35.
Ezekowitz MD, Pollack CV, Jr., Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018; 39: 2959-2971.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
